English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/150880
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients

AuthorsGahete, Manuel D.; Durán-Prado, M.; Hergueta-Redondo, Marta; Moreno-Bueno, Gema ; Luque, Raúl M.; Castaño, Justo P.
KeywordsBreast cancer
VEGF
Angiogenesis
sst5TMD4
Somatostatin receptor
Issue Date2016
PublisherImpact Journals
CitationOncotarget 7(37): 60110-60122 (2016)
AbstractThe truncated somatostatin receptor sst5TMD4 is associated with poor prognosis in breast cancer and increases breast cancer cell malignancy. Here, we examined the cellular/molecular mechanisms underlying this association, aiming to identify new molecular tools to improve diagnosis, prognosis or therapy. A gene expression array comparing sst5TMD4 stably-transfected MCF-7 cells and their controls (empty-plasmid) revealed the existence of profound alterations in the expression of genes involved in key tumoral processes, such as cell survival or angiogenesis. Moreover, sst5TMD4- overexpressing MCF-7 and MDA-MB-231 cells demonstrated increased expression/ production of pro-angiogenic factors and enhanced capacity to form mammospheres. Consistently, sst5TMD4-expressing MCF-7 cells induced xenografted tumors with higher VEGF levels and elevated number of blood vessels. Importantly, sst5TMD4 was expressed in a subset of breast cancers, where it correlated with angiogenic markers, lymphatic metastasis, and reduced disease-free survival. These results, coupled to our previous data, support a relevant role of sst5TMD4 in the angiogenic process and reinforce the role of sst5TMD4 in breast cancer malignancy and metastatic potential, supporting its possible utility to develop new molecular biomarkers and drug therapies for these tumors.
DescriptionGahete et al.
Publisher version (URL)https://doi.org/10.18632/oncotarget.11076
URIhttp://hdl.handle.net/10261/150880
DOI10.18632/oncotarget.11076
Identifiersdoi: 10.18632/oncotarget.11076
e-issn: 1949-2553
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
sst5TMD4.pdf7,01 MBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.